MovDisordV3, PascalFrancis, Curation, bibRecord, 003855

Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy

Identifieur interne : 003855 ( PascalFrancis/Curation ); précédent : 003854; suivant : 003856

Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy

Auteurs : O. Rascol [France] ; K. Sieradzan [Royaume-Uni] ; H. Peyro-Saint-Paul [France] ; C. Thalamas [France] ; C. Brefel-Courbon [France] ; J. M. Senard [France] ; P. Ladure [France] ; J. L. Montastruc [France] ; A. Lees [Royaume-Uni]

Source :

Movement disorders [ 0885-3185 ] ; 1998.

RBID : Pascal:98-0354352

Descripteurs français

Pascal (Inist)
- Ophtalmoplégie supranucléaire, Etude double insu, Randomisation, Essai croisé, Efaroxan, Agoniste, Récepteur α2-adrénergique, Chimiothérapie, Motricité, Traitement, Adulte.
Wicri :
- topic : Adulte.

English descriptors

KwdEn :
- Adult, Agonist, Chemotherapy, Crossover study, Double blind study, Efaroxan, Motricity, Randomization, Supranuclear ophthalmoplegia, Treatment, α2-Adrenergic receptor.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 13`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy`
A11	`01`	`1`		`@1 RASCOL (O.)`
A11	`02`	`1`		`@1 SIERADZAN (K.)`
A11	`03`	`1`		`@1 PEYRO-SAINT-PAUL (H.)`
A11	`04`	`1`		`@1 THALAMAS (C.)`
A11	`05`	`1`		`@1 BREFEL-COURBON (C.)`
A11	`06`	`1`		`@1 SENARD (J. M.)`
A11	`07`	`1`		`@1 LADURE (P.)`
A11	`08`	`1`		`@1 MONTASTRUC (J. L.)`
A11	`09`	`1`		`@1 LEES (A.)`
A14	`01`			`@1 Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital @2 Toulouse @3 FRA @Z 1 aut. @Z 4 aut. @Z 5 aut. @Z 6 aut. @Z 8 aut.`
A14	`02`			`@1 Department of Neurology, Manchester Royal Infirmary @3 GBR @Z 2 aut.`
A14	`03`			`@1 Institut de Recherche P. Fabre @2 Boulogne @3 FRA @Z 3 aut. @Z 7 aut.`
A14	`04`			`@1 National Hospital for Neurology and Neurosurgery @2 London @3 GBR @Z 9 aut.`
A20				`@1 673-676`
A21				`@1 1998`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000077139450090`
A44				`@0 0000 @1 © 1998 INIST-CNRS. All rights reserved.`
A45				`@0 23 ref.`
A47	`01`	`1`		`@0 98-0354352`
A60				`@1 P`
A61				`@0 A`
A64		`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C02	`01`	`X`		`@0 002B02B09A`
C03	`01`	`X`	`FRE`	`@0 Ophtalmoplégie supranucléaire @5 01`
C03	`01`	`X`	`ENG`	`@0 Supranuclear ophthalmoplegia @5 01`
C03	`01`	`X`	`SPA`	`@0 Oftalmoplejía supranuclear @5 01`
C03	`02`	`X`	`FRE`	`@0 Etude double insu @5 04`
C03	`02`	`X`	`ENG`	`@0 Double blind study @5 04`
C03	`02`	`X`	`SPA`	`@0 Estudio doble ciego @5 04`
C03	`03`	`X`	`FRE`	`@0 Randomisation @5 05`
C03	`03`	`X`	`ENG`	`@0 Randomization @5 05`
C03	`03`	`X`	`SPA`	`@0 Aleatorización @5 05`
C03	`04`	`X`	`FRE`	`@0 Essai croisé @5 06`
C03	`04`	`X`	`ENG`	`@0 Crossover study @5 06`
C03	`04`	`X`	`SPA`	`@0 Ensayo cruzado @5 06`
C03	`05`	`X`	`FRE`	`@0 Efaroxan @2 NK @2 FR @5 07`
C03	`05`	`X`	`ENG`	`@0 Efaroxan @2 NK @2 FR @5 07`
C03	`05`	`X`	`SPA`	`@0 Efaroxano @2 NK @2 FR @5 07`
C03	`06`	`X`	`FRE`	`@0 Agoniste @5 08`
C03	`06`	`X`	`ENG`	`@0 Agonist @5 08`
C03	`06`	`X`	`SPA`	`@0 Agonista @5 08`
C03	`07`	`X`	`FRE`	`@0 Récepteur α2-adrénergique @5 09`
C03	`07`	`X`	`ENG`	`@0 α2-Adrenergic receptor @5 09 @6 «α2-»Adrenergic receptor`
C03	`07`	`X`	`SPA`	`@0 Receptor α2-adrenérgico @5 09`
C03	`08`	`X`	`FRE`	`@0 Chimiothérapie @5 10`
C03	`08`	`X`	`ENG`	`@0 Chemotherapy @5 10`
C03	`08`	`X`	`SPA`	`@0 Quimioterapia @5 10`
C03	`09`	`X`	`FRE`	`@0 Motricité @5 13`
C03	`09`	`X`	`ENG`	`@0 Motricity @5 13`
C03	`09`	`X`	`SPA`	`@0 Motricidad @5 13`
C03	`10`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`10`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`10`	`X`	`GER`	`@0 Aufbereiten @5 17`
C03	`10`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`11`	`X`	`FRE`	`@0 Adulte @5 20`
C03	`11`	`X`	`ENG`	`@0 Adult @5 20`
C03	`11`	`X`	`SPA`	`@0 Adulto @5 20`
C07	`01`	`X`	`FRE`	`@0 Homme`
C07	`01`	`X`	`ENG`	`@0 Human`
C07	`01`	`X`	`SPA`	`@0 Hombre`
C07	`02`	`X`	`FRE`	`@0 Oeil pathologie @5 37`
C07	`02`	`X`	`ENG`	`@0 Eye disease @5 37`
C07	`02`	`X`	`SPA`	`@0 Ojo patología @5 37`
C07	`03`	`X`	`FRE`	`@0 Oculomotricité syndrome @5 38`
C07	`03`	`X`	`ENG`	`@0 Oculomotor syndrome @5 38`
C07	`03`	`X`	`SPA`	`@0 Oculomotricidad síndrome @5 38`
C07	`04`	`X`	`FRE`	`@0 Système nerveux pathologie @5 39`
C07	`04`	`X`	`ENG`	`@0 Nervous system diseases @5 39`
C07	`04`	`X`	`SPA`	`@0 Sistema nervioso patología @5 39`
C07	`05`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 40`
C07	`05`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`05`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`06`	`X`	`FRE`	`@0 Tronc cérébral syndrome @5 41`
C07	`06`	`X`	`ENG`	`@0 Brain stem syndrome @5 41`
C07	`06`	`X`	`SPA`	`@0 Tallo encefalico sindrome @5 41`
C07	`07`	`X`	`FRE`	`@0 Encéphale pathologie @5 42`
C07	`07`	`X`	`ENG`	`@0 Cerebral disorder @5 42`
C07	`07`	`X`	`SPA`	`@0 Encéfalo patología @5 42`
C07	`08`	`X`	`FRE`	`@0 Maladie dégénérative @5 43`
C07	`08`	`X`	`ENG`	`@0 Degenerative disease @5 43`
C07	`08`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 43`
N21				`@1 236`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002F69

Links to Exploration step

Pascal:98-0354352

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Sieradzan, K" sort="Sieradzan, K" uniqKey="Sieradzan K" first="K." last="Sieradzan">K. Sieradzan</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Manchester Royal Infirmary</s1>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Peyro Saint Paul, H" sort="Peyro Saint Paul, H" uniqKey="Peyro Saint Paul H" first="H." last="Peyro-Saint-Paul">H. Peyro-Saint-Paul</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institut de Recherche P. Fabre</s1>
<s2>Boulogne</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C." last="Brefel-Courbon">C. Brefel-Courbon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Ladure, P" sort="Ladure, P" uniqKey="Ladure P" first="P." last="Ladure">P. Ladure</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institut de Recherche P. Fabre</s1>
<s2>Boulogne</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Lees, A" sort="Lees, A" uniqKey="Lees A" first="A." last="Lees">A. Lees</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>National Hospital for Neurology and Neurosurgery</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">98-0354352</idno>
<date when="1998">1998</date>
<idno type="stanalyst">PASCAL 98-0354352 INIST</idno>
<idno type="RBID">Pascal:98-0354352</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">002F69</idno>
<idno type="wicri:Area/PascalFrancis/Curation">003855</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy</title>
<author><name sortKey="Rascol, O" sort="Rascol, O" uniqKey="Rascol O" first="O." last="Rascol">O. Rascol</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Sieradzan, K" sort="Sieradzan, K" uniqKey="Sieradzan K" first="K." last="Sieradzan">K. Sieradzan</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Manchester Royal Infirmary</s1>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Peyro Saint Paul, H" sort="Peyro Saint Paul, H" uniqKey="Peyro Saint Paul H" first="H." last="Peyro-Saint-Paul">H. Peyro-Saint-Paul</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institut de Recherche P. Fabre</s1>
<s2>Boulogne</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Thalamas, C" sort="Thalamas, C" uniqKey="Thalamas C" first="C." last="Thalamas">C. Thalamas</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Brefel Courbon, C" sort="Brefel Courbon, C" uniqKey="Brefel Courbon C" first="C." last="Brefel-Courbon">C. Brefel-Courbon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Senard, J M" sort="Senard, J M" uniqKey="Senard J" first="J. M." last="Senard">J. M. Senard</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Ladure, P" sort="Ladure, P" uniqKey="Ladure P" first="P." last="Ladure">P. Ladure</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Institut de Recherche P. Fabre</s1>
<s2>Boulogne</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Montastruc, J L" sort="Montastruc, J L" uniqKey="Montastruc J" first="J. L." last="Montastruc">J. L. Montastruc</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Lees, A" sort="Lees, A" uniqKey="Lees A" first="A." last="Lees">A. Lees</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>National Hospital for Neurology and Neurosurgery</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1998">1998</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Agonist</term>
<term>Chemotherapy</term>
<term>Crossover study</term>
<term>Double blind study</term>
<term>Efaroxan</term>
<term>Motricity</term>
<term>Randomization</term>
<term>Supranuclear ophthalmoplegia</term>
<term>Treatment</term>
<term>α2-Adrenergic receptor</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Ophtalmoplégie supranucléaire</term>
<term>Etude double insu</term>
<term>Randomisation</term>
<term>Essai croisé</term>
<term>Efaroxan</term>
<term>Agoniste</term>
<term>Récepteur α2-adrénergique</term>
<term>Chimiothérapie</term>
<term>Motricité</term>
<term>Traitement</term>
<term>Adulte</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Adulte</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>13</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>RASCOL (O.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SIERADZAN (K.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>PEYRO-SAINT-PAUL (H.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>THALAMAS (C.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BREFEL-COURBON (C.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SENARD (J. M.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>LADURE (P.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>MONTASTRUC (J. L.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>LEES (A.)</s1>
</fA11>
<fA14 i1="01"><s1>Departments of Clinical Pharmacology, Neurology and Clinical Investigation Center, University Hospital</s1>
<s2>Toulouse</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, Manchester Royal Infirmary</s1>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Institut de Recherche P. Fabre</s1>
<s2>Boulogne</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>National Hospital for Neurology and Neurosurgery</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>673-676</s1>
</fA20>
<fA21><s1>1998</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000077139450090</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1998 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>23 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>98-0354352</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B09A</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Ophtalmoplégie supranucléaire</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Supranuclear ophthalmoplegia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Oftalmoplejía supranuclear</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Etude double insu</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Double blind study</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Estudio doble ciego</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Randomisation</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Randomization</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Aleatorización</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Essai croisé</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Crossover study</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Ensayo cruzado</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Efaroxan</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Efaroxan</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Efaroxano</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Agonist</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Agonista</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Récepteur α2-adrénergique</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>α2-Adrenergic receptor</s0>
<s5>09</s5>
<s6>«α2-»Adrenergic receptor</s6>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Receptor α2-adrenérgico</s0>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>10</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Motricité</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Motricity</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Motricidad</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="GER"><s0>Aufbereiten</s0>
<s5>17</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Adulte</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Adult</s0>
<s5>20</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Adulto</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Oeil pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Eye disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Ojo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Oculomotricité syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Oculomotor syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Oculomotricidad síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Tronc cérébral syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Brain stem syndrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Tallo encefalico sindrome</s0>
<s5>41</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>42</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>42</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>43</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>43</s5>
</fC07>
<fN21><s1>236</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003855 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 003855 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:98-0354352
   |texte=   Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy

Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy

Source :

Descripteurs français

English descriptors

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri